EGFR and non-small cell lung carcinoma: Patients with stage IV non-squamous NSCLC, confirmed DEL19 or L858R EGFR mutations, and progression after EGFR-TKI therapy were randomized 1:1 to receive pembrolizumab (200 mg every three weeks for up to 35 cycles) or placebo along with four cycles of pemetrexed and carboplatin or cisplatin, followed by pemetrexed maintenance therapy.